Simanski C, Neugebauer E. Postoperative pain therapy. Chirurg 2003; 74: 254–274.
Hopf HW, Weitz S. Postoperative pain management. Arch Surg 1994; 129: 128–132.
Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542–2554.
Ashburn MA, Caplan A, Carr DB et al. Practice guidelines for acute pain management in the perioperative setting. Anesthesiology 2004; 100: 1573–1581.
Cashman J, McAnulty G. Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use. Drugs 1995; 49: 51–70.
Rusy LM, Houck CS, Sullivan LJ et al. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg 1995; 80: 226–229.
Moiniche S, Romsing J, Dahl JB, Tramer MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth Analg 2003; 96: 68–77.
Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91: 12221–12225.
Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002; 94: 55–59.
Buvanendran A, Kroin JS, Tuman KJ et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA 2003; 290: 2411–2418.
Sinatra RS, Shen QJ, Halaszynski T, Luther MA, Shaheen Y. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort-dependent pain and pulmonary function. Anesth Analg 2004; 98: 135–140.
Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481–1492.
Malan Jr TP, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC. Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003; 98: 950–956.
Tang J, Li S, White PF et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 2002; 96: 1305–1309.
Karamanlioglu B, Turan A, Memis D, Ture M. Preoperative oral rofecoxib reduces postoperative pain and tramadol consumption in patients after abdominal hysterectomy. Anesth Analg 2004; 98: 1039–1043.
Koizuka S, Saito S, Obata H et al. Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery. J Anesth 2004; 18: 9–13.
Reynolds LW, Hoo RK, Brill RJ, North J, Recker DP, Verburg KM. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage 2003; 25: 133–141.
Barton SF, Langeland FF, Snabes MC et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002; 97: 306–314.
Romsing J, Moiniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand 2004; 48: 525–546.
Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307–314.
Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N. An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg
2003; 97: 35–38.
Huang JJ, Taguchi A, Hsu H, Andriole Jr GL, Kurz A. Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial. J Clin Anesth 2001; 13: 94–97.
O'Hanlon DM, Thambipillai T, Colbert ST, Keane PW, Given HF. Timing of preemptive tenoxicam is important for postoperative analgesia. Can J Anaesth 2001; 48: 162–166.
Katz J. Preemptive analgesia: importance of timing. Can J Anesth 2001; 48: 105–114.
Steffen P, Seeling W, Reiser A, Rockemann M, Georgieff M. Differential indications for non-opioids for postoperative analgesia III. Analgesic effect of perioperative administration of metamizole plus diclofenac after spinal anesthesia. Anasthesiol Intensivmed Notfallmed Schmerzther 1997; 32: 496–501.
Celik JB, Tuncer S, Reisli R, Sarkilar G, Celik C, Akyurek C. A comparative study of the effect of rofecoxib (a COX-2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy. Arch Gynecol Obstet 2003; 268: 297–300.
Bekker A, Cooper PR, Frempong-Boadu A, Babu R, Errico T, Lebovits A. Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery. Neurosurgery 2002; 50: 1053–1057.
Meyer R. Rofecoxib reduces perioperative morphine consumption for abdominal hysterectomy and laparoscopic gastric banding. Anaesth Intens Care 2002; 30: 389–390.
Romsing J, Moiniche S, Mathiesen O, Dahl JB. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiol Scand 2005; 49: 133–142.
Apfelbaum JL, Gan TJ, Zhao S, Hanna D, Chen C. Reliability and validity of the perioperative opioid-related symptom distress scale. Anesth Analg 2004; 99: 699–709.
Bauer P. Multiple testing in clinical trials. Statist Med 1991; 10: 871–890.
Breitfeld C, Peters J, Vockel T, Lorenz C, Eikermann M. Emetic effects of morphine and piritramide. Br J Anaesth 2003; 91: 218–223.
Casarett D, Karlawish J, Sankar P, Hirschman K, Asch DA. Designing pain research from the patient's perspective: What Trial End Points Are Important to Patients With Chronic Pain? Pain Med 2001; 2: 309–316.
Katz N. Reporting of clinical trials of analgesia. J Thorac Cardiovasc Surg 2003; 127: 605.
Oberholzer-Gee F, Inamdar NS. Merck's recall of rofe-coxib – a strategic perspective. N Engl J Med 2004; 351: 2147–2149.
Kang JD, Georgescu HI, McIntyre-Larkin L, Stefanovic-Racic M, Donaldson III WF, Evans CH. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine 1996; 21: 271–277.
Kang JD, Georgescu HI, McIntyre-Larkin L, Stefanovic-Racic M, Evans CH. Herniated cervical intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine 1995; 20: 2373–2378.
Svensson CI, Yaksh TL. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002; 42: 553–583.
Gan TJ, Lubarsky DA, Flood EM et al. Patient preferences for acute pain treatment. Br J Anaesth 2004; 92: 681–688.
Kissin I. Preemptive analgesia. Why its effect is not always obvious. Anesthesiology 1996; 84: 1015–1019.
Kissin I. Preemptive analgesia. Anesthesiology 2000; 93: 1138–1143.
Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs. placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003; 60: 843–848.